CEO Michael Amoroso was paid $2,189,467 in fiscal year 2025, ↓ down 49.2% from fiscal year 2024, the 1st percentile of its disclosed peer group (SEC filing 0001140361-26-013757 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$2,189,467 ↓ Michael Amoroso total, FY2025 | 1st CEO pay percentile vs peers | — CEO-to-median pay ratio | 96.83% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
DTIL's next annual pay disclosure, estimated April 1, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Michael Amoroso | $650,875 | $451,294 | $1,025,086 | $0 | $0 | $0 | $62,212 | $2,189,467 |
| President, Chief Executive Officer and Director | ||||||||
| Alex Kelly | 472,525 | 222,220 | 417,060 | 0 | 0 | 0 | 22,311 | 1,134,116 |
| Chief Financial Officer | ||||||||
| Dario Scimeca | 445,875 | 193,558 | 252,000 | 0 | 0 | 0 | 20,208 | 911,641 |
| General Counsel and Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Michael Amoroso | $2,189,467 | $4,310,914 | $2,039,280 | ↓ −2,121,447 |
| Alex Kelly | 1,134,116 | 1,893,387 | 1,084,388 | ↓ −759,271 |
| Dario Scimeca | 911,641 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Precision Biosciences's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper DTIL reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name DTIL as a peer is temporarily unavailable — recheck shortly.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Geno Germano | Independent Director | $173,900 |
| Kevin J. Buehler | Chair of the Board | $192,650 |
| Melinda Brown | Independent Director | $163,150 |
| Shari Lisa Pir | Independent Director | — |
| Stanley R. Frankel, M.D | Director | $334,200 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Geno Germano | Director | 2026-05-20 | A | 21,000 | — | — | Common | Form 4 ↗ |
| Shari Lisa Pire | Director | 2026-05-20 | D | 21,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Melinda Brown | Director | 2026-05-20 | D | 21,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Melinda Brown | Director | 2026-05-20 | A | 21,000 | — | — | Common | Form 4 ↗ |
| Stanley Frankel | Director | 2026-05-20 | D | 21,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stanley Frankel | Director | 2026-05-20 | A | 21,000 | — | — | Common | Form 4 ↗ |
| Kevin J. Buehler | Director | 2026-05-20 | D | 21,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin J. Buehler | Director | 2026-05-20 | A | 21,000 | — | — | Common | Form 4 ↗ |
| Shari Lisa Pire | Director | 2026-05-20 | A | 21,000 | — | — | Common | Form 4 ↗ |
| Geno Germano | Director | 2026-05-20 | D | 21,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alex Kelly | Chief Financial Officer | 2026-06-01 | A | 193,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dario Scimeca | General Counsel and Secretary | 2026-06-01 | A | 107,604 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| J. Jefferson Smith | Chief Research Officer | 2026-06-01 | A | 57,389 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Amoroso | Director | 2026-06-01 | A | 573,888 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin J. Buehler | Director | 2026-06-03 | A | 20,979 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shari Lisa Pire | Director | 2026-06-03 | A | 20,979 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Geno Germano | Director | 2026-06-03 | A | 20,979 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stanley Frankel | Director | 2026-06-03 | A | 20,979 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Melinda Brown | Director | 2026-06-03 | A | 20,979 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Geno Germano | Director | 2026-09-25 | A | 2,609 | 6 | 16,385 | Common | Form 4 ↗ |
| Melinda Brown | Director | 2026-09-25 | A | 1,135 | 6 | 7,116 | Common | Form 4 ↗ |
| Stanley Frankel | Director | 2026-09-28 | A | 1,000 | 6 | 6,000 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Alex Kelly | RSU | — | — | — | — | — | $417,060 |
| Dario Scimeca | RSU | — | — | — | — | — | 252,000 |
| Michael Amoroso | RSU | — | — | — | — | — | 1,025,086 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Alex Kelly | $417,060 | $0 | $0 | 0.0% |
| Dario Scimeca | 252,000 | 0 | 0 | 0.0% |
| Michael Amoroso | 1,025,086 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Dario Scimeca | RSU | 50,000 | — | $208,000 |
| Alex Kelly | RSU | 82,750 | — | 344,240 |
| Dario Scimeca | RSU | 16,850 | — | 70,096 |
| Michael Amoroso | RSU | 138,842 | — | 577,583 |
| Dario Scimeca | RSU | 29,815 | — | 124,030 |
| Alex Kelly | RSU | 53,150 | — | 221,104 |
| Michael Amoroso | Option | 2,083 | 41.4 | — |
| Alex Kelly | RSU | 27,801 | — | 115,652 |
| Alex Kelly | RSU | 3,888 | — | 16,174 |
| Michael Amoroso | RSU | 203,390 | — | 846,102 |
| Michael Amoroso | RSU | 74,138 | — | 308,414 |
| Michael Amoroso | RSU | 8,888 | — | 36,974 |
| Dario Scimeca | RSU | 1,978 | — | 8,228 |
We believe that equity awards provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-21 | 18,696,193 | 612,836 | 18,504 | 96.83% | Passed |
| 2025 | 2025-05-28 | 3,389,745 | 261,406 | 102,189 | 92.84% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-21 | 96.83%a |
| 2025 | 2025-05-28 | 92.84%b |
a. Approved under the standard stated in the filing — “(3) Abstentions are not counted as "votes cast" and thus will have no effect on the approval of this proposal.”.
b. Approved under the standard stated in the filing — “(3) Abstentions are not counted as "votes cast" and thus will have no effect on the approval of this proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Stanley R. Frankel, M.DNot independent · Science and Technology (Chair) | $52,250 | $108,150 | $0 | $0 | $173,800 | $334,200 |
| Kevin J. BuehlerIndependent · Board Chair · Lead Independent Director · Audit · Nominating/Governance | 84,500 | 108,150 | 0 | 0 | 0 | 192,650 |
| Geno GermanoIndependent · Audit · Compensation (Chair) · Science and Technology | 65,750 | 108,150 | 0 | 0 | 0 | 173,900 |
| Melinda BrownIndependent · Audit (Chair) · Compensation | 55,000 | 108,150 | 0 | 0 | 0 | 163,150 |
| Shari Lisa PiréIndependent · Compensation · Nominating/Governance (Chair) | 54,250 | 108,150 | 0 | 0 | 0 | 162,400 |
| Michael AmorosoEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 6,250 / 3,750 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $311,750 |
| Equity awards (grant-date value) | $540,750 |
| All other compensation | $173,800 |
| Total cost of the board | $1,026,300 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Precision Biosciences names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Precision Biosciences.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Verve Therapeutics, Inc. | 2024 | Sekar Kathiresan | $639,231 | $1,683,000 | $4,727,372 | $378,972 | $7,442,663 |
| 2 | Intellia Therapeutics, Inc. | 2025 | John Leonard | 708,000 | 2,443,920 | 1,356,320 | 0 | 5,063,899 |
| 3 | Prime Medicine, Inc. | 2025 | Allan Reine | 606,212 | 0 | 2,828,798 | 402,000 | 3,894,187 |
| 4 | Editas Medicine, Inc. | 2025 | Gilmore O'Neill | 686,574 | 0 | 1,282,937 | 375,164 | 2,353,655 |
| 5 | Precision Biosciences | 2025 | Michael Amoroso | 650,875 | 1,025,086 | 0 | 0 | 2,189,467 |
| — | Sangamo Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Precision Biosciences | 115% | RSU 100 | not disclosed | Aon |
| Editas Medicine, Inc. | 91% | Options 100 | not disclosed | Pearl Meyer & Partners, LLC |
| Intellia Therapeutics, Inc. | 115% | Option 40 · RSU 40 · PSU 20 | Yes — TSR relative to the Nasdaq Biotechnology Index | Alpine |
| Prime Medicine, Inc. | 120% | not disclosed | not disclosed | Alpine Rewards |
| Sangamo Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Verve Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Radford Data & Analytics from Aon plc |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Michael Amoroso | DEF 14A | 2026-04-08 | 0001140361-26-013757 | Section “Summary Compensation Table” · page 39. As printed: 2,189,467. Filing ↗machine: r2 · c19 · span 829996–830005 |
| 2 | Section 01, Alex Kelly | DEF 14A | 2026-04-08 | 0001140361-26-013757 | Section “Summary Compensation Table” · page 39. As printed: 1,134,116. Filing ↗machine: r4 · c19 · span 837788–837797 |
| 3 | Section 01, Dario Scimeca | DEF 14A | 2026-04-08 | 0001140361-26-013757 | Section “Summary Compensation Table” · page 39. As printed: 911,641. Filing ↗machine: r6 · c19 · span 844622–844629 |
| 4 | Section 03, Alex Kelly RSU | DEF 14A | 2026-04-08 | 0001140361-26-013757 | Section “FUNCTION-DMD” · grants of plan-based awards table. Filing ↗machine: t230 · r4 · c13 · span 836584–836591 |
| 5 | Section 03, Dario Scimeca RSU | DEF 14A | 2026-04-08 | 0001140361-26-013757 | Section “FUNCTION-DMD” · grants of plan-based awards table. Filing ↗machine: t230 · r6 · c13 · span 843668–843675 |
| 6 | Section 03, Michael Amoroso RSU | DEF 14A | 2026-04-08 | 0001140361-26-013757 | Section “FUNCTION-DMD” · grants of plan-based awards table. Filing ↗machine: t230 · r2 · c13 · span 828801–828810 |
| 7 | Section 07, pay ratio | 10-K | 2026-03-12 | 0001628280-26-017019 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 8 | Section 08, Stanley R. Frankel, M.D | DEF 14A | 2026-04-08 | 0001140361-26-013757 | Section “Director Compensation”. As printed: 334,200. Filing ↗machine: r4 · c13 · span 1008427–1008592 |
| 9 | Section 08, Kevin J. Buehler | DEF 14A | 2026-04-08 | 0001140361-26-013757 | Section “Director Compensation”. As printed: 192,650. Filing ↗machine: t262 · r3 · c13 · span 1005575–1005733 |
| 10 | Section 08, Geno Germano | DEF 14A | 2026-04-08 | 0001140361-26-013757 | Section “Director Compensation”. As printed: 173,900. Filing ↗machine: t262 · r5 · c13 · span 1011305–1011463 |
| 11 | Section 08, Melinda Brown | DEF 14A | 2026-04-08 | 0001140361-26-013757 | Section “Director Compensation”. As printed: 163,150. Filing ↗machine: t262 · r2 · c13 · span 1002700–1002858 |
| 12 | Section 08, Shari Lisa Piré | DEF 14A | 2026-04-08 | 0001140361-26-013757 | Section “Director Compensation”. As printed: 162,400. Filing ↗ |
| 13 | Section 08, Michael Amoroso | DEF 14A | 2026-04-08 | 0001140361-26-013757 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 14 | Section 02, Geno Germano 2026-05-20 | Form 4 | 2026-05-22 | 0001628280-26-037533 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 15 | Section 02, Shari Lisa Pire 2026-05-20 | Form 4 | 2026-05-22 | 0001628280-26-037534 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 16 | Section 02, Melinda Brown 2026-05-20 | Form 4 | 2026-05-22 | 0001628280-26-037536 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Melinda Brown 2026-05-20 | Form 4 | 2026-05-22 | 0001628280-26-037536 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Stanley Frankel 2026-05-20 | Form 4 | 2026-05-22 | 0001628280-26-037537 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Stanley Frankel 2026-05-20 | Form 4 | 2026-05-22 | 0001628280-26-037537 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Kevin J. Buehler 2026-05-20 | Form 4 | 2026-05-22 | 0001628280-26-037539 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Kevin J. Buehler 2026-05-20 | Form 4 | 2026-05-22 | 0001628280-26-037539 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Shari Lisa Pire 2026-05-20 | Form 4 | 2026-05-22 | 0001628280-26-037534 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Geno Germano 2026-05-20 | Form 4 | 2026-05-22 | 0001628280-26-037533 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Alex Kelly 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040215 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Dario Scimeca 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040220 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, J. Jefferson Smith 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040223 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Michael Amoroso 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040212 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Kevin J. Buehler 2026-06-03 | Form 4 | 2026-06-05 | 0001628280-26-041037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Shari Lisa Pire 2026-06-03 | Form 4 | 2026-06-05 | 0001628280-26-041039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Geno Germano 2026-06-03 | Form 4 | 2026-06-05 | 0001628280-26-041041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Stanley Frankel 2026-06-03 | Form 4 | 2026-06-05 | 0001628280-26-041043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Melinda Brown 2026-06-03 | Form 4 | 2026-06-05 | 0001628280-26-041045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Geno Germano 2026-09-25 | Form 4 | 2026-09-29 | 0001628280-26-063766 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Melinda Brown 2026-09-25 | Form 4 | 2026-09-29 | 0001628280-26-063767 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Stanley Frankel 2026-09-28 | Form 4 | 2026-09-30 | 0001628280-26-063980 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 06, 2026 vote | Form 8-K | 2026-05-26 | 0001628280-26-038220 | Item 5.07 · say-on-pay result. As reported: 96.83% (votes for as printed: 18,696,193). Filing ↗ |
| 37 | Section 06, 2025 vote | Form 8-K | 2025-06-03 | 0000950170-25-080564 | Item 5.07 · say-on-pay result. As reported: 92.84% (votes for as printed: 3,389,745). Filing ↗ |
| 38 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 39 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 40 | Section 09b board cost (computed) | Computed | — | — | Cash 311,750 + equity 540,750 + all other 173,800 = 1,026,300, summed across the director compensation table rows.machine: formula: Σ = 1,026,300 |
| 41 | Verve Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-25 | 0000950170-25-058325 | CEO total compensation as printed in Verve Therapeutics, Inc.'s own proxy. As printed: 7,442,663. Filing ↗machine: r2 · c20 · span 327433–327442 |
| 42 | Intellia Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-197283 | CEO total compensation as printed in Intellia Therapeutics, Inc.'s own proxy. As printed: 5,063,899. Filing ↗machine: r2 · c25 · span 749290–749299 |
| 43 | Prime Medicine, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026697 | CEO total compensation as printed in Prime Medicine, Inc.'s own proxy. As printed: 3,894,187. Filing ↗machine: r2 · c42 · span 285179–285188 |
| 44 | Editas Medicine, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001650664-26-000037 | CEO total compensation as printed in Editas Medicine, Inc.'s own proxy. As printed: 2,353,655. Filing ↗machine: t42 · r2 · c12 · span 545455–545464 |
| 45 | Precision Biosciences (subject), Section 10b CEO total | DEF 14A | 2026-04-08 | 0001140361-26-013757 | CEO total compensation as printed in Precision Biosciences's own proxy. As printed: 2,189,467. Filing ↗machine: r2 · c19 · span 829996–830005 |
| 46 | Section 10a, Editas Medicine, Inc. reciprocity | DEF 14A | — | 0001650664-26-000037 | Editas Medicine, Inc.'s most recent proxy was read; its disclosed peer group does not include Precision Biosciences. Filing ↗ |
| 47 | Section 10a, Intellia Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-197283 | Intellia Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Precision Biosciences. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.